Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05893979 · ClinicalTrials.gov registry record · NA

Myopia Control Spectacle Lens Cessation Study

A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.

Active
Registry status
NA
Development phase
90
Enrollment target
8
Study locations

NCT05893979 is a NA study of Myopia and Juvenile Myopia that is active but no longer recruiting, run by SightGlass Vision. The registered enrollment target is 90 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (66% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05893979, a NA study of Myopia and Juvenile Myopia, is active but no longer recruiting, sponsored by SightGlass Vision.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
8
Study locations

Study Summary

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.

Interventions

  • DEVICE Spectacle Lenses

Study Locations (8)

California

  • Golden Optometric Group - Whittier

Florida

  • Omega Vision Center PA - Longwood

Kansas

  • Kannarr Eye Care - Pittsburg

Missouri

  • Advanced Eyecare PC - Raytown

New York

  • Sacco Eye Group - Vestal

Tennessee

  • Total Eye Care - Memphis

Texas

  • Vision Optique - Houston

Utah

  • William J Bogus, OD, FAAO - Salt Lake City

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2023-06-23
Est. Completion 2026-07-31
Phase NA

Sponsor

SightGlass Vision

8 total trials

What the Registry Record Tells You About NCT05893979

The ClinicalTrials.gov registry entry for NCT05893979 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (66% lower). The listed sponsor is SightGlass Vision, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which Spectacle Lenses is the first listed.

NCT05893979 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT05893979 about?

NCT05893979 is a clinical study titled "Myopia Control Spectacle Lens Cessation Study". To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.

What is the current status of trial NCT05893979?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-06-23. Estimated completion is 2026-07-31.

What conditions does trial NCT05893979 study?

This clinical trial studies the following conditions: Myopia, Juvenile Myopia, Myopia Progression.

What interventions are being tested in trial NCT05893979?

The interventions under investigation include: Spectacle Lenses (DEVICE).

Who is sponsoring clinical trial NCT05893979?

This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05893979 being conducted?

This trial has 8 study locations across California, Florida, Kansas, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.